RxDoctor Payments Data

Taylor Clark

Gerontology · Philadelphia, PANPI 1235657545

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,259 of the $1,956 with a category attached, or 64.4%. 16 manufacturers reported payments, led by Livanova USA, Inc. at 50.6% of the total. 2025 is the largest year on record at $1,633, more than ten times the $19 reported in 2022.

$1,956in general payments, 2019–2025

Across 35 payments — averaging $55.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$989
  • AbbVie$208
  • SK Life Science, Inc.$178
  • Phathom Pharmaceuticals, Inc.$129
  • Biogen$90
  • UCB, Inc.$59
  • plus $301 from 10 others

What the payments were for

  • Travel & lodging$69736%
  • Food & beverage$1,25964%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,956 in reported general payments places this provider in the 85th percentile of 383 gerontology providers in Pennsylvania.

See all gerontology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,709
Medicare patients
100
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam31$55,509
NayzilamMidazolam19$11,817
Lacosamide29$4,640
Clobazam20$1,896
Levetiracetam32$930
Phenobarbital16$241
Topiramate11$212
Lamotrigine14$159
Gabapentin16$95
Risperidone12$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$59$67,32750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 383 gerontology providers in Pennsylvania.

Other gerontology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →